

**Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (original): A stent for delivering drugs to a vessel in a body comprising:  
a stent framework including a plurality of reservoirs formed therein, the reservoirs  
formed using a femtosecond laser;  
a drug polymer positioned in the reservoirs; and  
a polymer layer positioned on the drug polymer.

Claim 2 (original): The stent of claim 1 wherein the stent framework comprises  
one of a metallic base or a polymeric base.

Claim 3 (original): The stent of claim 2 wherein the stent framework base  
comprises a material selected from the group consisting of stainless steel, nitinol, tantalum,  
MP35N alloy, platinum, titanium, a suitable biocompatible alloy, a suitable biocompatible  
polymer, and a combination thereof.

Claim 4 (original): The stent of claim 1 wherein the reservoirs comprise  
micropores.

Claim 5 (original): The stent of claim 4 wherein the micropores have a diameter  
of about 20 microns or less.

Claim 6 (original): The stent of claim 4 wherein the micropores have a diameter  
in the range of about 20 microns to about 50 microns.

Claim 7 (original): The stent of claim 4 wherein the micropores have a depth in  
the range of about 10 to about 50 microns.

Claim 8 (original): The stent of claim 4 wherein the micropores have a depth of about 50 microns.

Claim 9 (original): The stent of claim 4 wherein the micropores extend through the stent framework having an opening on an interior surface of the stent and an opening on an exterior surface of the stent.

Claim 10 (original): The stent of claim 4 further comprising:  
a cap layer disposed on the interior surface of the stent framework, the cap layer covering at least a portion of the through-holes and providing a barrier characteristic to control an elution rate of a drug in the drug polymer from the interior surface of the stent framework.

Claim 11 (original): The stent of claim 1 wherein the reservoirs comprise channels along an exterior surface of the stent framework.

Claim 12 (original): The stent of claim 1 wherein the drug polymer comprises a therapeutic compound.

Claim 13 (original): The stent of claim 12 wherein the therapeutic compound is selected from the group consisting of an antisense agent, an antineoplastic agent, an antiproliferative agent, an antithrombogenic agent, an anticoagulant, an antiplatelet agent, an antibiotic, an anti-inflammatory agent, a therapeutic peptide, a gene therapy agent, a therapeutic substance, an organic drug, a pharmaceutical compound, a recombinant DNA product, a recombinant RNA product, a collagen, a collagenic derivative, a protein, a protein analog, a saccharide, a saccharide derivative, and a combination thereof.

Claim 14 (original): The stent of claim 1 wherein the drug polymer comprises a first layer of a first drug polymer having a first pharmaceutical characteristic and the polymer layer comprises a second drug polymer having a second pharmaceutical characteristic.

Claim 15 (original): The stent of claim 1 further comprising:

a barrier layer positioned between the drug polymer and the polymer layer.

Claim 16 (original): The stent of claim 15 wherein the barrier layer comprises a polymer selected from the group consisting of a silicone-urethane copolymer, a polyurethane, a phenoxy, ethylene vinyl acetate, polycaprolactone, poly(lactide-co-glycolide), polylactide, polysulfone, elastin, fibrin, collagen, chondroitin sulfate, a biocompatible polymer, a biostable polymer, a biodegradable polymer, and a combination thereof.

Claim 17 (original): The stent of claim 1 wherein the drug polymer comprises a first drug-polymer layer including an anti-proliferative drug, a second drug-polymer layer including an anti-inflammatory drug, and a third drug-polymer layer including an antisense drug, the antisense drug, the anti-inflammatory drug and the anti-proliferative drug being eluted in a phased manner when the stent is deployed.

Claim 18 (original): The stent of claim 1 wherein the polymer layer comprises a cap layer.

Claim 19 (original): The stent of claim 18 wherein the cap layer is positioned on the drug polymer and at least a portion of an interior surface or an exterior surface of the stent framework.

Claim 20 (original): The stent of claim 18 wherein the cap layer comprises a polymer selected from the group consisting of a silicone-urethane copolymer, a polyurethane, a phenoxy, ethylene vinyl acetate, polycaprolactone, poly(lactide-co-glycolide), polylactide, polysulfone, elastin, fibrin, collagen, chondroitin sulfate, a biocompatible polymer, a biostable polymer, a biodegradable polymer, and a combination thereof.

Claim 21 (original): The stent of claim 1 further comprising:  
an adhesion layer positioned between the stent framework and the drug polymer.

Claim 22 (original): The stent of claim 21 wherein the adhesion layer is selected from the group consisting of a polyurethane, a phenoxy, poly(lactide-co-glycolide), polylactide, polysulfone, polycaprolactone, an adhesion promoter, and a combination thereof.

Claim 23 (original): The stent of claim 1 further comprising:  
a catheter coupled to the stent framework.

Claim 24 (original): The stent of claim 23 wherein the catheter includes a balloon used to expand the stent.

Claim 25 (original): The stent of claim 23 wherein the catheter includes a sheath that retracts to allow expansion of the stent.

Claim 26 (withdrawn): A method of manufacturing a drug-polymer stent, comprising:  
providing a stent framework;  
cutting a plurality of reservoirs in the stent framework using a high power laser;  
applying a drug polymer to at least one reservoir;  
drying the drug polymer;  
applying a polymer layer to the dried drug polymer; and  
drying the polymer layer.

Claim 27 (withdrawn): The method of claim 26 wherein the plurality of reservoirs are cut with a femtosecond laser.

Claim 28 (withdrawn): The method of claim 26 wherein the drug polymer is applied using a technique selected from the group consisting of spraying, dipping, painting, brushing and dispensing.

Claim 29 (withdrawn): The method of claim 26 wherein the drug polymer is applied to at least one reservoir using a mask.

Claim 30 (withdrawn): The method of claim 26 wherein the polymer layer comprises one of a drug polymer, a barrier layer, or a cap layer.

Claim 31 (withdrawn): The method of claim 26 wherein the polymer layer is applied using a technique selected from the group consisting of spraying, dipping, painting, brushing and dispensing.

Claim 32 (withdrawn): The method of claim 26 wherein the polymer layer is applied to at least a portion of an interior surface or an exterior surface of the stent framework using a mask.

Claim 33 (withdrawn): The method of claim 26 further comprising:  
applying an adhesion layer to at least one reservoir prior to the application of the drug polymer.

Claim 34 (withdrawn): A method of treating a vascular condition, comprising:  
positioning a stent within a vessel of a body, the stent including a stent framework with a plurality of micropore reservoirs formed therein using a femtosecond laser, a drug polymer positioned in the reservoirs, and a polymer layer positioned on the drug polymer;  
expanding the stent; and  
eluting at least one drug from at least an exterior surface of the stent.